SCIENCE: An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

  • Posted on June 11, 2017
  • by Redenlab
  • Speech

Speech sensitive to treatment response

J Neurol. 2015 May;262(5):1344-53. doi: 10.1007/s00415-015-7719-2

Tags: , , ,

Related Post

Redenlab study featured in the Huberman Lab Podcast

  • Posted on 27 April, 2023
    Redenlab have been featured in the Huberman Lab Podcast for their study on “Adults with a history of recreational cannabis...
    Read more

    The L16HTHOUSE Study

    • Posted on 30 March, 2023
      L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
      Read more

      Temporary Assessment of Language in Kabuki Syndrome (TALK) Study

      • Posted on 30 March, 2023
        Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate communication. These...
        Read more